AGORA FINANCIAL

JANUARY 2017

TECHNOLOGY PROFITS CONFIDENTIAL

— *Profit Today From Bleeding-Edge Technology and Innovation* —

A Look Ahead: Driverless Revolution on the Horizon

INSIDE THIS ISSUE

Gerald Celente
Editor

Ray Blanco
Portfolio Analyst



By 2025, every major automaker will market self-driving cars.

Industry headlines will tell you that this trend is coming faster than it really is. But I predict the path to full autonomy in vehicles will be slower than more familiar technology trends.

In an industry beset with frequent and serious recalls, the technological and legal liability challenges are considerable. And it slows progress down.

But while the transition to driverless vehicles may not come as fast as some suggest, already, the automotive industry is making strides in adding driverless technology to new makes and models of vehicles.

It's just the beginning. And soon this technology will hit its stride.

Let's be honest: No tech investor made a fortune by putting his money into a technology that's already well established.

Step by step, cars are getting closer to driving themselves.

As the technology progresses, there are profits to make now. And 2017 will be a breakout year for this technology.

Look How Far We've Come

Take a walk around a nice car dealership — cars that can brake and park themselves, spot distracted pedestrians and steer away from possible collisions are now standard gear on pricier models.

Self-steering is a major milestone, but a relatively easy one to pass. Tiny cameras mounted on a car's front corners spot traffic-lane lines and send information to an on-board computer. The computer interprets the image. It decides whether the cameras are seeing lane lines. If they are, the computer sends a steady stream of instructions to servomechanisms that adjust the steering this way or that to stay between the lines.

Sound complicated? It's a piece of cake for current autonomous technology.

More advanced systems not only detect objects ahead, but also identify them. For example, Mercedes' electronic eye connects cameras with an on-board computer using 3D-imaging software and a bank of more than 1.5 million images. That lets it differentiate among a cardboard box, puddle and a tot on a tricycle.

If your car lacks driverless features, you can install add-ons from companies such as Gosher and Mobileye (yes, the same Mobileye you can find in the *Technology Profits* portfolio.)

It just scratches the surface of what's out there… and what's to come.

Advances like these take us well into what the U.S. National Highway Traffic Administration refers to as Level 2 of automated vehicles.

There are five levels. Level 0 means the car is a brainless pile of metal and plastic. Level 1 cars take on a simple task, such as controlling cruising speed. Level 2 vehicles have a repertoire of skills; Tesla's "Autopilot" is the best-known example.

Level 4 is an automated ride that functions in a defined area, such as an industrial park or downtown neighborhood. Level 5 lets you nap in the back seat while the car goes anywhere you tell it to.

What happened to Level 3?

Carmakers are reluctant to enter Level 3. It's where drivers and cars share control. That raises complicated issues: In an emergency, what if the car and driver assume the other will take charge? Which tasks will be left to which? Will the carmaker and driver blame the other for accidents?

Several car companies hope to avoid that quagmire by skipping Level 3 and going right to Level 4. Ford, for example, promises to have Level 4 cars on the market by 2021.

The Big Trend For 2017

While the path to driverless vehicles will unfold in incremental steps overall, the growth will evolve quicker in commercial arenas, where trucks and transport vehicles can be better controlled within defined routes.

Commercial transport vehicles, especially in regions where well defined routes and traffic patterns are accommodating, will follow driverless trucks in this evolution. It's already happening. In 2017, it will continue to take shape.

Otto, an autonomous truck start up, teamed up with Budweiser to make the first autonomous truck delivery.

As this new technology unfolds, driverless technology will have a ripple effect.

You'll see it expand into cybersecurity, augmented reality and the job market. This isn't just cameras mounted on your car. This is going to revolutionize multiple industries.

Keep an eye on this space.

The 2016 *Technology Profits Confidential* Year End Review

By Ray Blanco

Our tilted planet has entered that part of the solar orbit when the Northern Hemisphere's days are short, nights are long and cold and we look forward to the end of the great turn in space we call the year.

It's been a great year for us on many fronts. We've nailed some of the year's greatest tech trends. By looking ahead and beating the herd, we've taken a number of double- and triple-digit profits over the past 11 months.

Some of our recommendations remain buys, some have become sells, and some I am going to recommend we continue holding. As in past years, I'd like to take this

Contact our Customer Care Center:

1-800-708-1020 or 443-268-0468

or e-mail customerservice@agorafinancial.com

Technology Profits Confidential is published monthly for $99 per year by Agora Financial LLC, 808 St. Paul Street, Baltimore, MD 21202-2406, www.agorafinancial.com. Subscriptions are US $99 per year for U.S. residents. **Executive Publisher:** Addison Wiggin; **Publisher:** Aaron Gentzler; **Managing Editor:** Amanda Stiltner; **Associate Editor:** Amanda Garbart; **Graphic Design:** Max Canner

final issue to look back, reassess our existing positions and tell you what moves to make.

Read on for the full story.

The Technology Portfolio

It's been a banner year for many tech companies, and we've been in the right place, at the right time, with the right picks in the *Technology Profits* portfolio.

Advanced Micro Devices (NASDAQ: AMD) is riding high on a tsunami powered by a virtual reality seaquake. There is plenty of growth room ahead even though AMD isn't the market share leader in GPUs. That honor goes to Nvidia… but more on that in a bit. AMD, however, has a custom chip business, making it very attractive to gaming console companies that prefer tweaked GPU designs over plain-vanilla offerings.

More recently, the earth has rumbled beneath AMD shares as the market's awakened to the company's potential in artificial intelligence and deep learning applications.

We recommended AMD in May once it became clear that the company was in a better financial position to develop and grow its place as the No. 2 company in the graphics processing space. It's looking even better now that Google has sourced AMD for some of its server GPUs for its upcoming Google Cloud Platform.

AMD is now a clean double in just seven months. Let's take a profit on a portion of our shares and keep riding the rest.

Recommendation: Sell a third of your Advanced Micro Devices (NASDAQ: AMD) shares.

Now we turn to the No. 1 player in the dedicated GPU space, and that's **Nvidia (NASDAQ: NVDA)**. We entered Nvidia early last year, and it has been full of win for us.

Nvidia has everything I look for in a tech company. It has the most advanced technology in its space, and a relentless research and development program. Moreover, the company has leveraged it for growth far outside the gaming space — although this remains Nvidia's biggest market and the company's core.

Nvidia, however, is busy turning its GPUs into a general purpose computing technology, and CEO Jen-Hsun Huang has astutely used it to bootstrap the fastest-growing, most transformational fields in computing.

This includes autonomous driving. Nvidia previously supplied some of the sumptuous entertainment features in Tesla Motors vehicles. However, the company has recently become the supplier of the brains for these cars. Tesla's vehicles will now have autonomous driving features built upon NVDA's PX platform — making Elon Musk boast about how his electric cars are half a decade of everyone else's in terms of self-driving sophistication.

A growing presence in the data center as well as artificial intelligence and deep learning is also helping Nvidia is rack up blowout quarter after blowout quarter. We've recently taken a 339% profit on a portion of our NVDA shares, and we're currently up 366%. I recommend we keep holding.

Recommendation: Keep holding your remaining Nvidia (NASDAQ: NVDA) shares.

Intel (NASDAQ: INTC) is a recent addition for us, having joined the portfolio in October. I've long stood on the sidelines with Intel, watching growth slow in the PC space and the company's efforts to penetrate the smartphone market coming to naught. I predicted Intel's smartphone failure in this newsletter all the way back in 2010, when the company tried to muscle in on a constellation of competitors all using technology licensed from ARM Holdings.

That's changing fast, however. Intel has recently opened up its world-class semiconductor manufacturing for use by other tech companies. This will allow Intel to vicariously participate in the smartphone space to a greater extent by manufacturing ARM-based chips for others. And as an ARM licensee itself, Intel could join the fray. Has Intel thrown in the towel for its own x86 architecture in this area of computing? It sure looks that way.

Intel is up for some competition from Taiwan Semiconductor, which recently announced it would start generating revenues from the next process shrink to 10 nanometer chips, but it wouldn't surprise me to see companies using ARM-based processors switch to Intel. That could include mobile computing giants like Apple and Qualcomm.

And let's not forget, many, if not the vast majority, of the coming wave of smart, connected internet of things devices will use ARM-based tech for its broad support and lower power consumption features. Intel gets a stronger foot in that door with this move.

INTC Intel Corp.



Even better… Intel is determined not to be left behind in the artificial intelligence space. Intel has moved aggressively to buy AI startups, and it recently announced the availability of its first server CPUs with built-in AI features.

Intel shares are nearly flat from our recommendation. It's still priced to buy, and in the meantime, you get to enjoy a reliable dividend just south of 3%.

Recommendation: Buy Intel (NASDAQ: INTC) up to $39 per share.

Mobileye (NYSE: MBLY) isn't to be ignored in the autonomous driving space. Yes, it lost Tesla to Nvidia, but it still has partnership deals with almost all of the world's major automobile makers.

Right now, MBLY is being selected to provide advanced automated safety features like emergency braking — which I like to think of as "autonomous driving light." Upcoming safety standards are going to make these features standard on nearly all new cars sold in the U.S. and elsewhere.

Mobileye, however, has hardly budged after an excellent quarter. We're almost even from our original entry price of $39.58 set when we recommended this company in late April. Even worse, MBLY shares are down significantly from a 52-week high of $51 set in August.

Is the market worried about emerging competition? Nvidia and Qualcomm are emerging threats… and even Intel is joining the fray, with a $250 million push into this area announced just last month.

For now, I am going to recommend we stay in wait-and-see mode. If the situation deteriorates, however, that will likely change.

Recommendation: Hold your Mobileye (NYSE: MBLY) shares.

Our automation play, **Cognex Corp. (NASDAQ:CGNX)**, has surged over the past month as the company has beat expectations on both the top and bottom lines. Automation isn't just a "thing"; it's the story of the Industrial Revolution, one that's only picking up steam as machines get smarter and more able to handle the drudgery of jobs humans used to do.

Even the Chinese are moving their manufacturing more and more in this direction. China needs to remain competitive with lower-wage countries, and it's trying to do that by automating everything.

And political promises to the contrary, even if manufacturing does come back to the USA, it won't bring back nearly all the jobs lost. The machines will happily slave away in a sweatshop for cheap, without strikes and without complaints. Consumers are all too happy to pay the lower prices.

We're up a cool 20% since our October recommendation, with CGNX shares taking a breather as I write this. I'm waiting for the next leg up as CGNX enables the automated factory.

Recommendation: Keep holding your Cognex (NASDAQ: CGNX) shares.

We picked **Glu Mobile (NASDAQ: GLUU)** in the wake of Nintendo's wildly successful augmented reality game based on the Pokémon franchise. As a major developer of mobile games, Glu sees virtual and augmented reality as part of its future growth. In fact, the company has already released VR games on platforms like the Samsung Gear, which uses a smartphone as the display portion of a VR headset.

However, the company has been decidedly mum on virtual and augmented reality prospects. Samsung's Gear remains one of the most popular VR headsets, mostly because of its low cost. In fact, I got one for free included with my smartphone purchase as part of a Black Friday deal.

However, a review of the most popular VR games[1] for this platform shows Glu holding none of the spots… even though the Gear is a smartphone-based platform and Glu has largely built its business on smartphones. In short, GLUU may be too stuck to more traditional smartphone games to profit from the emerging augmented and virtual reality market any time soon.

Recommendation: Sell Glu Mobile (NASDAQ: GLUU).

Facebook (NASDAQ: FB) is another big virtual reality play. The company released its flagship Oculus Rift headset earlier this year. Virtual reality remains a big part of Facebook's growth plan, and the company bet big when it moved early to buy Oculus[2]. While VR is still at an early stage of adoption, the company is pushing the new tech hard. It is, for example, rolling out virtual reality tours of physical locations[3], as well as VR roadshows.

Recommendation: Keep holding Facebook (NASDAQ: FB).

An aerospace play that has been flat for us is **ViaSat (NASDAQ: VSAT)**. The company is an operator of high-end, high-performance communications satellites. The company is currently gobbling up the commercial aviation market. ViaSat-enabled internet access is now available on hundreds of airplanes, with hundreds more coming online in a recent deal with American Airlines[4].

ViaSat is maximizing its investment in its sole satellite, the record breaking ViaSat-1. However, the company remains on track to launch the more powerful ViaSat-2, to be followed by the even more powerful ViaSat-3. Access to the internet has become as important as running water and electricity, and consumers and organizations demand it whether flying high over the Atlantic or tucked away in a remote and poorly accessible location.

ViaSat's success with its high-performance orbital hardware shows that the market for satellite communications is a large one if you can give the market what it wants: high-speed internet anytime, anywhere.

Recommendation: Keep holding ViaSat (NASDAQ:VSAT).

NVE Corp. (NASDAQ: NVEC) was our February "spintronics" play. Nearly the entire semiconductor industry — nearly all electronics we use and have ever used — work by exploiting the unique properties of the subatomic particle called the electron.

But here's the thing: We largely use the electron's charge. However, the electron has additional quantum properties. One of them is called "spin."

NVE is one of the few pure-play tech companies playing with an electron's spin. NVE plays with spin to build supersensitive sensors and actuators that are used deep in the guts of many delicate devices.

NVE could one day leverage this tech into a new type of superdense, persistent, energy-efficient memory.

However, the company has been busy in other ways. One very exciting possibility is a pathogen-detection system that has captured the interest of the Department of Agriculture. NVE's tech is so sensitive that it can detect incredibly small quantities of bacteria scattered thinly in relatively vast amounts of medium. This is more than detecting the proverbial needle in a haystack… it's the equivalent of detecting a single needle in the entire Mall of America.

The company has proceeded through early phases of development for this pathogen-detection system and continues to earn grants from the Department of Agriculture. The reason for interest is pretty obvious: Such a system would make a killer food and water safety platform.

The company continues to grow revenues, and its pathogen-detection system… nondilutively funded by the U.S. government… creates the potential for a truly transformational change at this company with a market cap of just $326 million. NVEC shares have been on a tear all month. We're up 55% so far. Plus, you get a 6% dividend even at today's price (it was a whopping 8% at the time I made my recommendation). Let's this winner keep runnin'.

Recommendation: Keep holding your NVE Corp. (NASDAQ: NVEC).

Stolen identities. Hacked consumer records. Compromised election vote worries. Stolen government emails. Websites and internet services suffering wide-scale outages because of attacks.

We've become so dependent on technology to do everything. Tech's great, but it's also a huge vulnerability.

That's why the future is so bright for solution providers like our November pick **Imperva Inc. (NYSE: IMPV)**, our July pick **Palo Alto Networks (NYSE: PANW)** and our December 2015 pick **CyberArk Software (NASDAQ: CYBR)**. These cybersecurity stocks are up 10%, 16%, and 13%, respectively.

They all handle cybersecurity from a different angle. Imperva provides a unique system to mitigate or block distributed denial of service (DDoS) attacks, Palo Alto has some of the best firewall tech in the business, and CyberArk differentiates itself by world-class privileged accounts protection, helping to prevent insider attacks from hackers that have acquired keys to the digital vault.

Cybersecurity remains a growing field that will lift many boats, especially with best-in-class tech companies like the ones we've added.

Recommendations: Buy Imperva Inc. (NYSE: IMPV) up to $41. Keep holding CyberArk (NASDAQ: CYBR) and Palo Alto Networks (NYSE: PANW).

The Biotech Portfolio

Biotechnology hasn't had nearly so good a year as tech. The Nasdaq Biotechnology Index is down over 17% year to date, greatly lagging the Nasdaq Composite, which has turned in a respectable 7% gain so far.

However, clouds might be clearing from the horizon. One big reason for biotech's wild moves over the past couple of months has been political. Hillary Clinton promised a war on pharma, spooking investors.

Donald Trump, however has struck a much more friendly tone. Promises for biotech and patient-friendly FDA reform, increased funding for medical research and other measures mean that the Trump election could end up proving very kind for biotech investors by comparison.

However, the performance of individual biotech stocks is often far removed from the performance of the sector as a whole. A clinical trial surprise or regulatory approval can rapidly generate a double- or even triple-digit gain for a biotech name even if the overall sector is moving down.

The opposite can be true, of course, which is why biotech can often be looked at as the ultimate stock picker's market. That said, our biotech portfolio hasn't performed nearly as well as tech. Let's look into some of our picks.

BlueBird bio (NASDAQ: BLUE) is a gene editing pioneer working on curing genetic diseases such sickle cell anemia, beta thalassemia and other diseases. The company is also leveraging its platform in order to engineer aggressive immune system cells to heal patients with cancer.

Bluebird has declined with the overall market, although it has also had its own stumbles. When some patients who had received the company's LentiGlobin therapy had their anemias return, BLUE shares tanked. The company, however, has worked out manufacturing issues and has a new version of its engineered bone marrow stem cell product in trials right now.

December could bring a major catalyst for BLUE shares. The company will be presenting new data on this therapy at the annual meeting of the American Society of Hematology. A positive report could bring back confidence in prospects for this company's revolutionary gene therapy platform and boost shares from their currently depressed price.

Recommendation: Keep holding bluebird bio (NASDAQ: BLUE).

French gene therapy pioneer **Cellectis (NASDAQ: CLLS)** has also sold off this year, but not for reasons intrinsic to its technology platform. The company is working in the wildly popular CAR-T cancer immunotherapy space. It's at an earlier stage of clinical development than some of its CAR-T competitors; however, I believe the path it's following could eventually make it the most successful.



Source: Cellectis.com

The company is working on changing the economics of this cell-based therapy by making a universal, one-size-fits-all line of cells. It's also developing a way to control the activity of these immune cells, making them safer for patients.

Recommendation: Buy Cellectis (NASDAQ: CLLS) up to $30.

One gene company I am less positive on is **Alnylam Pharmaceuticals (NASDAQ: ALNY)**. Alnylam treats genetic disease in a different way from BLUE. It doesn't directly edit the genes responsible. It modifies the way these gene codes are translated into proteins inside of cells.

ALNY shares plummeted when a therapy for a life-threatening genetic disorder called ATTR amyloidosis appeared to have caused more deaths than a placebo. The company has a newer-generation drug in Phase 3 trials for the same disease, but a competitor using similar technology called Ionis failed in the same indication… also for severe safety issues.

Alnylam may ultimately succeed, but two failures, at two different companies, for the same disease, using similar RNA/antisense technology, greatly raises the risk of further failure.

Recommendation: Sell Alnylam Pharmaceuticals (NASDAQ: ALNY).

NeuroDerm (NASDAQ: NDRM) is improving Parkinson's disease therapy by taking the two popular and long-used drugs, levodopa and carbidopa, and making them available through a constant delivery pump system. Together, these two drugs raise dopamine levels in the brain, stabilizing many of the difficult symptoms of this disease. The company is running multiple late-stage trials, with catalysts coming up over the next 12–24 months, followed by application to market with regulatory authorities.

Recommendation: Buy NeuroDerm (NASDAQ: NDRM) up to $20.

Nektar Therapeutics (NASDAQ: NKTR) has been in the portfolio since 2014. It's never been a strong performer, although we're up 14% right now. There's good reason to believe we could be up more than that in the next few months with this drug delivery specialist.

The company will be wrapping up two Phase 3 trials for two different antibiotics by early next year. Both are inhalable versions of existing antibiotics designed to help patients with stubborn lung and respiratory infections.

Recommendation: Buy Nektar Therapeutics

(NASDAQ: NKTR) up to $17.00.

I recommended **OncoMed Therapeutics (NASDAQ: OMED)** based on its unique and exciting approach to stamping out cancer. The company believes the reason many cancers come back is because existing therapies only kill adult tumor cells. However, there remain cancerous stem cells lurking in the body that can repopulate tumors with new, resistant adult cancer cells.

OMED shares took a dive earlier this year when a clinical trial failed, and they haven't bounced back. It appears the market has largely discounted the potential of its platform. With OncoMed, I we need to wait and see if there will be positive clinical data before deciding to jump back in.

Recommendation: Sell OncoMed Pharmaceuticals (NASDAQ: OMED).

Gilead Sciences has earned many billions of dollars from its revolutionary hep C therapy. **Enanta Pharmaceuticals (NASDAQ: ENTA)** has helped pioneer similar hepatitis C therapies with its partner AbbVie. The major sales, however, have not materialized. And since Enanta earns a royalty on those sales, neither have the big earnings.

The hep C market is maturing, patients are being cleared out by being cured and sales are expected to begin winding down. In a way these drug sales are a victim of their own success and with that, so will Enanta's revenues from this market.

Recommendation: Sell Enanta Pharmaceuticals (NASDAQ: ENTA).

Inovio Pharmaceuticals (NASDAQ: INO) is pursuing a unique vaccine technology. It created DNA constructs, called plasmids, which can direct cells in the body to produce a desired antigen. This antigen then trains the immune system to attack a pathogen of choice — even cancer.

The company's development plans, however, keep getting delayed. Recently, the company's lead vaccine candidate for treating precancerous cervical lesions was held by the FDA. We don't yet have a date we can point to for when the company could start a Phase 3 trial for this vaccine. FDA clinical holds are fraught with regulatory risk for biotech companies. I recommend we move out of INO for now.

Recommendation: Sell your Inovio Pharmaceuticals (NASDAQ: INO) shares.

Actinium Pharmaceuticals (NYSE: ATNM) has been the biggest biotech loser in our portfolio. The company's delay in launching a Phase 3 trial for its cancer radio immunotherapy has weighed down greatly on the share price.

However, the company has commenced a Phase 3 trial for patients with acute myeloid leukemia earlier this year. The drug, Iomab-B, is designed to clear out bone marrow cells in patients with AML with a targeted, short range pulse of radiation delivered using engineered antibodies.

This therapy holds the potential for being far more tolerable than existing chemotherapies. This is an important consideration, since so many AML patients are older and weaker and don't tolerate existing drugs.

If ATNM succeeds in posting positive Phase 3 data, we could see gains in the thousands of percent from today's price. It isn't an exaggeration if we consider the company's current $53 million market cap. Data from this trial are due by the first half of 2018, however, so patience is key. In the meantime, the company expects interim Phase 2 results for a different AML drug designed to clear out leukemic cells from the bloodstream in mid-2017.

Recommendation: Keep holding your Actinium Pharmaceuticals (NASDAQ: ATNM) shares.

In closing, 2016 was a banner year for the *Technology Profits Confidential* model portfolio. The star was Nvidia, as I mentioned above.

We twice took partial profits — 206% in August and 339% in November. The one-third position we still hold in the open model portfolio is up 366% as I write.

In the year ahead, we'll be going after more Nvidia-sized ideas. The positions we're saying goodbye to today clear the road for the more compelling ideas we have in store for you.

Thanks for subscribing to *Technology Profits Confidential*.

We love hearing from our subscribers. Feel free to drop us a line! Email me at AskRay@AgoraFinancial.com with your comments and questions. Your feedback may be featured in a future alert or issue.

Technology Profits Confidential Open Positions

COMPANY	SYMBOL	BUY DATE	BUY PRICE	CURRENT PRICE	GAIN/LOSS
Computer Technology					
AeroVironment Inc.	AVAV	12/27/13	$28.58	$29.26	2.38%
InvenSense, Inc.	INVN	4/2/14	$23.10	$7.98	-65.45%
Integrated Device Technology	IDTI	7/27/15	$19.14	$23.45	22.52%
CyberArk Software Ltd	CYBR	12/28/15	$44.96	$48.98	8.94%
NVE	NVEC	2/4/16	$46.35	$67.68	46.02%
ViaSat	VSAT	4/1/16	$72.89	$70.96	-2.65%
MobilEye	MBLY	4/28/16	$39.58	$37.26	-5.86%
Nvidida Corp	NVDA	2/6/15	$20.38	$93.39	358.24%
Advanced Micro Devices, Inc**	AMD	5/31/16	$4.50	SELL**	SELL**
Palo Alto Networks	PANW	7/5/16	$117.84	$129.35	9.77%
NXP Semiconductors	NXPI	8/1/16	$83.17	$98.02	17.85%
Cognex Corp.	CGNX	9/6/16	$49.69	$59.21	19.16%
Intel Corp.	INTC	10/4/16	$37.90	$34.71	-8.42%
Gaming Technology					
Facebook	FB	7/18/16	$118.71	$117.31	-1.18%
Glu Mobile	GLUU	7/18/16	$2.64	SELL	SELL
Biotechnology					
Nektar Therapeutics, Inc.	NKTR	3/3/14	$14.12	$12.80	-9.35%
Enanta Pharmaceuticals Inc	ENTA	5/30/14	$37.65	SELL	SELL
Inovio Pharmaceuticals	INO	10/29/14	$11.09	SELL	SELL
Actinium Pharmaceuticals, Inc	ATNM	12/2/14	$5.54	$1.02	-81.59%
Cempra Pharmaceuticals	CEMP	12/30/14	$23.50	$7.80	-66.81%
Alnylam Pharmaceuticals	ALNY	2/27/15	$100.57	SELL	SELL
Lam Research Corp	LRCX	3/27/15	$71.15	$102.89	44.61%
Neuroderm, Ltd	NDRM	6/4/15	$14.99	$19.09	27.35%
Johnson & Johnson	JNJ	6/30/15	$97.34	$112.03	15.09%
bluebird bio Inc	BLUE	9/1/15	$128.86	$78.95	-38.73%
OncoMed Pharmaceuticals	OMED	9/30/15	$15.56	SELL	SELL
Cellectis	CLLS	3/3/16	$25.80	$17.39	-32.60%
Imperva Inc.	IMPV	11/1/16	$36.25	$37.40	3.17%

Note: Returns are based on recommended entry and exit prices as mentioned in the *Technology Profits Confidential* e-mail alerts. Brokers' fees are not taken into consideration when calculating returns. If you are not receiving the *Technology Profits Confidential* e-mail alerts, please send us an e-mail to customerservice@agorafinancial.com. All numbers are believed to be correct. **Prices as of 12/6/16.**
****Sell a third of your AMD shares**

For citations and references used in this issue, click here.